Bansal Aditya, Bhende Muna, Sharma Tarun, Bhende Pramod, Mukherjee Suchetana
Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.
Vitreoretinal Services, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal, India.
Indian J Ophthalmol. 2017 Aug;65(8):758-760. doi: 10.4103/ijo.IJO_1003_16.
Treatment guidelines for symptomatic polypoidal choroidal vasculopathy (PCV) have been described, but the management of recurrent or recalcitrant PCV is a challenge. The newer anti-vascular endothelial growth factor: aflibercept has shown promise in the treatment of both treatment naive and recalcitrant PCV in studies outside India. We present the minimum 6 months results of intravitreal aflibercept in recurrent and recalcitrant PCV in Indian eyes after multiple injections of bevacizumab/ranibizumab with or without photodynamic therapy. Of 10 eyes, 7 resolved of which 4 recurred needing continued aflibercept. Three of the ten eyes did not show a response. To the best of our knowledge, this is the first report from India in this challenging situation.
有症状的息肉状脉络膜血管病变（PCV）的治疗指南已被描述，但复发性或难治性PCV的管理是一项挑战。新型抗血管内皮生长因子阿柏西普在印度以外的研究中已显示出在初治和难治性PCV治疗中的前景。我们展示了在印度患者眼中，多次注射贝伐单抗/雷珠单抗联合或不联合光动力疗法后，玻璃体内注射阿柏西普治疗复发性和难治性PCV至少6个月的结果。10只眼中，7只病情缓解，其中4只复发，需要继续注射阿柏西普。10只眼中有3只没有反应。据我们所知，这是印度在这种具有挑战性的情况下的首份报告。
